Eye Diseases Clinical Trial
Official title:
Familial Exudative Vitreoretinopathy Clinical and Molecular Studies
This study will examine the extent of the vision problem in familial exudative
vitreoretinopathy (FEVR) and try to identify the genes responsible for this hereditary eye
disorder. Patients with FEVR have incomplete formation of blood vessels in the periphery of
the retina (the inner part of the eye that is responsible for vision). As a result, abnormal
vessels can form and retinal detachment and vitreous bleeding can occur, causing significant
vision loss. Vision loss usually begins in childhood, gradually worsening over time. Some
patients eventually become blind.
Patients of all ages with FEVR and their family members may be eligible for this study.
Participants undergo the following tests and procedures:
- Family history, especially regarding eye disease. A family tree is drawn.
- Blood draw for genetic testing related to FEVR.
- Eye examination to assess visual acuity (eye chart test) and eye pressure, and to
examine pupils, lens, retina and eye movements. The pupils are dilated with drops for
this examination.
- Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected
into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina
are taken using a camera that flashes a blue light into the eye. The pictures show if
any dye has leaked from the vessels into the retina, indicating possible blood vessel
abnormality.
- Patients affected with FEVR will also undergo DEXA scan to look for osteoporosis. X-rays
are used to scan the hip, forearm and spine for bone density measurements.
Background: Familial exudative vitreoretinopathy (FEVR) is a rare hereditary disorder of the
retinal vasculature characterized by abrupt cessation of the growth of peripheral retinal
capillaries. FEVR seems to exhibit significant phenotypic and genotypic variability but since
this is a rare disease the clinical and genetic characteristics of the disease have not been
extensively studied so far. Correlation of phenotypes with certain genotypes have not been
made yet. Clinical findings can vary from very mild disease with only subtle changes of the
peripheral retinal vasculature without symptoms to severe disease with retinal
neovascularization, retinal exudates, vitreoretinal adhesions, peripheral vitreous opacities,
retinal folds and tractional retinal detachment. The condition remarkably resembles
retinopathy of prematurity but affected patients do not have a history of prematurity or
supplementary oxygen use.
The disorder is usually inherited as an autosomal dominant trait but few families show
x-linked or autosomal recessive inheritance. A significant number of patients with autosomal
dominant FEVR show linkage to 11q13-q23 (EVR1). Two genes in this locus have recently been
shown to be associated with the disease. FZD4, the gene that encodes for Frizzled-4, the Wnt
receptor, is one of them. It has been estimated by recent studies that 20-30% of patients
with autosomal dominant FEVR show mutations in FZD4. LRP5 (low-density-lipoprotein
receptor-related protein 5), a Wnt co-receptor, was recently shown to be mutated in
approximately 15% of cases. One large autosomal dominant pedigree has shown linkage to
11p13-p12 locus (EVR3) and this gene has not yet been identified. It now becomes obvious that
more genes are associated with the autosomal dominant type of the disease. Most of the
patients with the x-linked type have mutations in the Norrie disease gene (EVR2). The
autosomal recessive form of the disease is much rarer and linkage studies have not yet been
performed.
Aims: The objectives of this protocol are to study the clinical characteristics of FEVR, and
also to assist in identifying the location and sequence of corresponding genes. Since one of
the genes so far identified, LRP5, is also causing the osteoporosis-pseudoglioma syndrome, an
inherited disorder with severe osteoporosis, we would also like to know if FEVR patients,
especially those with mutations in LRP5 also have some degree of osteoporosis. Localization
and identification of the responsible gene will help us understand the pathogenesis of FEVR
and possibly the mechanism of retinal angiogenesis and lead to potential treatments.
Methods: Patients as well as available family members are to be evaluated by physical
examination and fluorescein angiography, in order to clinically characterize the inheritance
pattern in each family. Blood will be obtained by all participating subjects for the
molecular studies.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
| Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
| Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
| Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
| Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
| Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
| Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
| Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
| Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
| Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
| Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
| Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
| Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
| Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Completed |
NCT05211089 -
Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
|
||
| Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|